

Curriculum Vitae

NAME

Timothy Dudley Clay

PERSONAL INFORMATION

Birthdate 26/06/1981
Place of Birth Subiaco, Western Australia

Phone – private rooms 08 6465 9200
Fax – private rooms 08 6465 9250
Phone – mobile 0411 038 720

Email tim@drtimclay.com.au

Website www.drtimclay.com.au

EDUCATION

2012 – 2017 **University of Melbourne** – Doctor of Medical Science
“Adenocarcinoma of the lung – correlation of histopathology, molecular pathology and *in vivo* inflammatory markers, with clinical outcomes.”

2011 **University of Melbourne / Peter MacCallum Cancer Centre**
Specialist Certificate in Clinical Research (Oncology)
H1 Honours

1999 – 2004 **University of Western Australia**
Bachelor of Medicine and Bachelor of Surgery with Honours

EMPLOYMENT

July 2017 – Ongoing	Medical Oncologist Icon Cancer Care, Midland, WA
Feb 2015 – Ongoing	Medical Oncologist St John of God Hospital, Subiaco, WA
Feb 2015 – Ongoing	Medical Oncologist Genesis Cancer Care, Joondalup, WA
Mar 2014 – Sept 2017	Medical Oncologist Rockingham General Hospital, WA
Mar 2014 – Feb 2015	Medical Oncologist Royal Perth Hospital, WA
Jan 2014 – Feb 2014	Locum Medical Oncologist Tweed Heads Hospital, NSW
Aug 2013 – Dec 2013	Locum Medical Oncologist St Vincent’s Hospital, Melbourne
June 2013	Locum Medical Oncologist Hervey Bay Hospital, Queensland
Feb 2013 – Jan 2014	Locum VMO – Medical Oncology Cabrini Hospital, Malvern, Victoria
Feb 2013 – Dec 2013	Clinical Skills Coach (2 nd year Graduate Medicine Course) St Vincent’s Clinical School, University of Melbourne
Feb 2012 – July 2017	Oncology Research Fellow St Vincent’s Hospital, Melbourne

Jan 2012 –
Dec 2012 Locum Medical Fellow
Cabrini Hospital, Malvern, Victoria

Feb 2011 –
Feb 2012 Advanced Trainee – Medical Oncology
St Vincent’s Hospital, Melbourne

Feb 2010 –
Feb 2011 Advanced Trainee – Medical Oncology
Andrew Love Cancer Centre, Barwon Health, Geelong

April 2008 –
January 2010 Basic Physician Trainee – Medical Registrar
Royal Perth Hospital

Sept 2007 –
March 2008 Basic Physician Trainee – Resident Medical Officer
Royal Perth Hospital

April 2007 –
Aug 2007 Basic Surgical Trainee – General Surgical Registrar
Royal Perth Hospital

Feb 2006 –
March 2007 Basic Surgical Trainee – Resident Medical Officer
Royal Perth Hospital

Jan 2005 –
Jan 2006 Intern
Royal Perth Hospital

TRAINING AND PROFESSIONAL DEVELOPMENT

Nov 2018 Convenor – Clinical Oncology Society of Australia (COSA)
Annual Scientific Meeting

2016 –
Ongoing Board Member and Co-Principal Investigator
Bendat Respiratory Research and Development Committee Fund
St John of God Hospital, Subiaco

- 2015 Australia and New Zealand Breast Cancer Trials Group
Organising Committee Meeting – Annual Scientific Meeting
Perth WA
- 2015 Australasian Lung Cancer Trials Group
Preceptorship in Lung Cancer – 17th/18th April
- 2013 Australasian Gastrointestinal Trials Group
Preceptorship in Colorectal Cancer – 16th/17th August
- 2013 Royal Australasian College of Physicians
PREP Supervisor Workshop – 31st July
- 2012 Fellow – Royal Australasian College of Physicians
- 2012 Australia and Asia Pacific Clinical Oncology Research Development
(ACORD) Workshop
- 2010 – Advanced Trainee – Medical Oncology
2012 Royal Australasian College of Physicians
- 2010 Basic Sciences of Oncology Program
Medical Oncology Group of Australia
- 2007 – Basic Physician Trainee
2009 Royal Australasian College of Physicians
July 2009 – RACP Clinical Examination
March 2009 – RACP Written Examination
- 2008 Advanced Life Support Course
Australian Resuscitation Council

2006 – Basic Surgical Trainee
August 2007 Royal Australasian College of Surgeons
February 2007 – Part 1 Written and Clinical Examinations
Courses:
June 2006 – Care of the Critically Ill Surgical Patient (CCrISP Course)
August 2006 – Australia and New Zealand Surgical Skills Education and Training (ASSET) Course
May 2007 – Emergency Management of Severe Trauma (EMST) Course

2005 Intern Skill Development Certificate
Royal Perth Hospital

PROFESSIONAL MEMBERSHIPS

Medical Oncology Group of Australia
Clinical Oncology Society of Australia
Australian Medical Association (WA)
International Association for the Study of Lung Cancer
Australia and New Zealand Breast Cancer Trials Group
Australasian Lung Cancer Trials Group
Australasian Gastro-Intestinal Trials Group
Australia and New Zealand Urogenital and Prostate Cancer Trials Group
American Society for Clinical Oncology (ASCO)
European Society of Medical Oncology (ESMO)

Medical Registration: Medical Board of Australia / AHPRA
Registration Number: MED0001220713
General and Specialist Registration (Physician – Medical Oncology)

AWARDS / PRIZES

2012 – 2014	Australian Postgraduate Award University of Melbourne
2012	Fellowship Australia and Asia Pacific Clinical Oncology Research Development (ACORD) Workshop
2012	BMS Trainee Travel Award Medical Oncology Group of Australia Annual Scientific Meeting
2011	GSK Trainee Annual Scientific Meeting Travel Award Medical Oncology Group of Australia Annual Scientific Meeting
2007	Highly Commended (Early Career Teaching Category) – Excellence in Teaching Awards University of Western Australia Faculty of Medicine, Dentistry and Health Sciences.
2004	Person of the Year 2004 West Australian Medical Students' Society
2003	UWA Graduates Association Prize in Medicine (5 th Year)

CLINICAL TRIALS EXPERIENCE

Principal Investigator at St John of God Hospital, Subiaco, WA:

1. BR34 – Stage IV NSCLC (NCT03057106)
2. ARCS-Multi – Stage IV NSCLC and Stage IV triple negative breast cancer (NCT03102320)
3. STORM VLA-B (Keynote 200) – Stage IV NSCLC and Urothelial Carcinoma (NCT02043665)
4. TRITON2: Prostate Carcinoma (NCT02952534)
5. TRITON3: Prostate Carcinoma (NCT0297594)
6. NIVORAD: Stage IV NSCLC (ACTRN12616000352404)
7. DUBLIN-3: Stage IV NSCLC (NCT02504489)
8. RANGE: Stage IV Urothelial Carcinoma (NCT02426125)

2015 – Ongoing	St John of God Hospital, Subiaco – Co-Investigator on Multiple Clinical Trials in Oncology
2014	Royal Perth Hospital – Co-Investigator on Multiple Clinical Trials in Oncology
2011 – 2013	St Vincent’s Hospital, Melbourne – Sub Investigator on Multiple Clinical Trials in Oncology
2010	Andrew Love Cancer Centre, Geelong – Sub Investigator on Multiple Clinical Trials in Oncology
2006	Co-Investigator – Vitamin D supplementation following biliopancreatic diversion for morbid obesity (PI – Mr Leon Cohen)

1. Hart NH, Galvão DA, Saunders C, Taaffe DR, Feeney KT, Spry NA, Tsoi D, Martin H, Chee R, Clay T, Redfern AD, Newton RU. Mechanical suppression of osteolytic bone metastases in advanced breast cancer patients: a randomised controlled study protocol evaluating safety, feasibility and preliminary efficacy of exercise as a targeted medicine. *Trials*, accepted 30 Nov 2018, in press.
2. Clay TD, Bowyer SE. Dabrafenib and Trametinib treatment-associated fevers in metastatic melanoma causing extreme elevation in procalcitonin in the absence of infection. *Anticancer Drugs*. 2018; 29(8); 802 – 805
3. Craven P, Daly C, Oates R, Sikotra N, Clay T, Gabbay E. Inferior vena cava filters (IVCFs): a review of use and application to international guidelines at a single Australian centre; implications of venous thromboembolism associated with malignancy. *Pulm Circ*, 2018 Apr-Jun; 8(2)
4. Clay TD, Russell PA, Do H, Sundararajan V, Conron M, Wright GM, Solomon B, Dobrovic A, McLachlan SA, Moore MM. EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. *Med Oncol*, 2017; 34 (10); 175
5. Chia PL, Devitt B, Clay T, McLachlan SA, Mitchell P, John T. Attitudes of patients and physicians on repeat biopsies for lung cancer. *Expert Review of Quality of Life in Cancer Care*, 2017; 2 (3); 181 – 202
6. Clay TD, Russell PA, Do H, Sundararajan V, Conron M, Wright GM, Dobrovic A, Moore MM, McLachlan SA. Associations between the IASLC/ATS/ERS Lung Adenocarcinoma Classification and *EGFR* and *KRAS* mutations. *Pathology*, 2016; 48 (1); 17 – 24.
7. Lambe G, Le P, Clay TD. A finding with a diagnosis – I just can't put my finger on it. *British Medical Journal Case Reports* 2014; Dec 22.
8. Clay TD, Do H, Sundararajan V, Moore MM, Conron M, Wright GM, McLachlan SA, Dobrovic A, Russell PA. The clinical relevance of pathologic subtypes in metastatic adenocarcinoma. *Journal of Thoracic Oncology* 2014; 9(5); 654 – 663.
9. Russell PA, Yu Y, Do H, Clay TD, Moore MM, Wright GM, Conron M, Wainer Z, Dobrovic A, McLachlan SA. *EGFR* gene copy number alterations are not a useful screening tool for predicting *EGFR* mutation status in lung adenocarcinoma. *Pathology* 2014; 46(1); 32 – 36
10. Clay TD, Dimitriou J, McNally OM, Russell PA, Newcomb AE, Wilson AM. Intravenous leiomyomatosis with intracardiac extension – A review of diagnosis and management with an illustrative case. *Surgical Oncology* 2013; 22(3); e44 – e52

11. Clay TD. Pinch-Off Syndrome – a simple test is the best. *Internal and Emergency Medicine* 2012; 7 (Suppl 2); S141 – S143.
12. Clay TD, Ashley D. Acute Pain Associated with Oxaliplatin Infusion: case report and literature review. *Journal of Oncology Pharmacy Practice* 2012; 18(4): 421 – 424.
13. Einarsdottir K, Preen DB, Clay TD, Kiely L, Holman CD, Cohen LD. Effect of a Single ‘Megadose’ Intramuscular Vitamin D (600,000 IU) Injection on Vitamin D Concentrations and Bone Mineral Density Following Biliopancreatic Diversion Surgery. *Obesity Surgery* 2010; 20; 732 – 737

POSTERS

1. Daly C, Craven P, Sikotra N, Cheruvu S, Gabbay E, Arellano A, Clay T. A single centre experience of *Pneumocystis jirovecii* pneumonia (PJP) in patients with solid organ malignancy. Abstract 392, Clinical Oncology Society of Australia ASM, Perth, WA November 2018
2. Craven P, Daly C, Sikotra N, Clay T, Gabbay E. Attitudes to inferior vena cava filters (IVCFs) among medical oncologists, haematologists and respiratory physicians. Abstract 330, Clinical Oncology Society of Australia ASM, Perth, WA November 2018
3. Skiba R, Sikotra N, Ball T, Arellano A, Gabbay E, Clay T. Adherence to antibiotic guidelines in the management of febrile neutropenia. Abstract 326, Clinical Oncology Society of Australia ASM, Perth, WA November 2018
4. Clay TD, Daly C, Craven P, Sikotra N, Cheruvu S, Gabbay E, Arellano A. Effect of *pneumocystis jirovecii* pneumonia (PJP) on morbidity and mortality in oncology patients: A single centre experience. *J Clin Oncol* 36, 2018 (suppl; abstr e22088). ASCO 2018 ASM
5. Shapiro J, Voskoboynik M, Krieger L, Byard I, Clay T, Ganju V, Abida W, Chowdhury S, Watkins S, Despain D, Simmons A, Go J, Golsorkhi T, Scher H. Trial of Rucaparib in ProsTate IndicatiONs 2 (TRITON2): An International, Multicentre, Open-Label Phase 2 Study of the PARP Inhibitor Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD). Australian Urogenital and Prostate Cancer Meeting, July 2017, Melbourne Australia
6. Krieger L, Byard I, Clay T, Ganju V, Ryan CJ, Watkins S, Despain D, Simmons A, Miyamoto E, Golsorkhi T, Chowdhury S. Trial of Rucaparib in ProsTate IndicatiONs 3 (TRITON3): An International, Multicentre, Randomised, Open-Label Phase 3 Study of Rucaparib vs Physician’s Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous

Recombination Deficiency (HRD). Australian Urogenital and Prostate Cancer Meeting, July 2017, Melbourne Australia

7. Clay TD, Russell PA, Do H, Sundararajan V, Conron M, Wright GM, Solomon B, Dobrovic A, McLachlan SA, Moore MM. *EGFR* Mutations Are Not Associated With Activation of IL6 / JAK1 / STAT3 in Resected Lung Adenocarcinoma. Australian Lung Cancer Conference, October 2014, Brisbane QLD.
8. Clay TD, Russell PA, Do H, Sundararajan V, Conron M, Wright GM, Dobrovic A, Moore MM, McLachlan SA. Frequency of *EGFR* and *KRAS* Mutations by IASLC / ATS / ERS Subtypes in an Australian Cohort. Australian Lung Cancer Conference, October 2014, Brisbane QLD.
9. Chia PL, Devitt BA, Clay TD, McLachlan SA. What do patients with cancer think about re-biopsy of tumours? A qualitative study. Medical Oncology Group of Australia Annual Scientific Meeting, Aug 2014.
10. Clay TD, Do H, Sundararajan V, Moore MM, Conron M, Wright G, McLachlan SA, Dobrovic A, Russell PA. Metastatic sites with a major component of solid pattern pulmonary adenocarcinoma are associated with shorter survival with systemic therapy and infrequent *EGFR* mutations.
15th World Conference on Lung Cancer, October 2013, Sydney.
11. Clay TD, Chua W, Moore MM. An Elevated Neutrophil Lymphocyte Ratio Predicts Survival in Metastatic Non Small Cell Lung Cancer. *Asia Pacific Journal of Clinical Oncology* 2012; 8(s2); 49.
Medical Oncology Group of Australia Annual Scientific Meeting, Aug 2012
12. Clay TD, Bell R. Weight and Body Mass Index (BMI) Change During Adjuvant Treatment for Early Breast Cancer- A Retrospective Review. *Asia Pacific Journal of Clinical Oncology* 2011; 7(s3); 54.
Medical Oncology Group of Australia Annual Scientific Meeting, Aug 2011.

PRESENTATIONS

1. Ho Chi Minh City Cancer Congress, Vietnam, 30 November 2017 (sponsored by MSD Vietnam)
 - a. Immuno-oncology – How it has changed practice in lung cancer
 - b. Immune checkpoint inhibitors for advanced NSCLC – experience sharing from Australia
2. Cancer Nurses Society of Australia – 19th Annual Congress, May 2016, Cairns QLD
Invited Speaker:
 - Breast Cancer Care Symposium – “Advances in Breast Cancer Treatment”
 - ImmunoOncology Symposium – “Cancer & the Immune System”
 - Concurrent Session – “On Target, a story of mabs and nibs”
3. “Older Adult Oncology”
Cancer Nurses Society of Australia WA Branch Education Seminar October 2015
4. “Rats in the Ranks – Chemotherapy Selection in Colorectal Carcinoma”
Invited Presentation – Royal Australasian College of Surgeons ASM
07/05/2015, Perth WA
5. “Blood Tests – Back to Basics”
Cancer Nurses Society of Australia WA Branch Education Seminar 14/03/2015
6. “Adenocarcinoma of the lung – know your enemy”
Invited presentation, St Vincent’s Hospital Grand Rounds, April 2012
7. “Intrusive Thoughts in Invasive Illness – Medical Oncology for the CL Psychiatrist” –

Invited Presentation – Minding the Body 2011
Seminar Series for Advanced Trainees in Consultation Liaison Psychiatry
Royal Australian and New Zealand College of Psychiatrists
Alfred Hospital, Melbourne
8. Clay TD, Cohen L, Preen DB. Once Yearly ‘Megadose’ Intramuscular Vitamin D (600,000 IU): A Simple, Safe and Effective Method to Normalise Vitamin D Levels After BPD Surgery. *Surgery for Obesity and Related Diseases* 2007; 3(3); 354

Presented at Annual Meeting of the American Society of Bariatric Surgery, San Diego USA, 13/06/2007

REFEREES

1. A/Prof Sue-Anne McLachlan
Medical Oncologist

Cancer Centre, Level 1, Daly Wing
35 Victoria Parade
St Vincent's Hospital, Fitzroy, Victoria 3065

Phone: 03 9288 3155
Fax: 03 9288 3172
Mobile: 0419 395 696
Email: Sue-Anne.MCLACHLAN@svha.org.au

2. Dr Melissa Moore
Medical Oncologist

Cancer Centre, Level 1, Daly Wing
35 Victoria Parade
St Vincent's Hospital, Fitzroy, Victoria 3065

Phone: 03 9288 3155
Fax: 03 9288 3172
Mobile: 0408 240 734
Email: Melissa.Moore@svha.org.au